SureTrader
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 602
Posts 91,448
Boards Moderated 32
Alias Born 09/05/02
160x600 placeholder
Dow Pares Losses To End Volatile Session Off 1.1%
The flight from risky assets accelerated Monday, pummeling shares of big global banks and sending gold prices to their biggest one-day gain in more than a year.
More Top Equities Stories Of The Day
Pay Dividends Or Keep Ratings
CMO Today: Viacom's Dauman Replaces Redstone as Chairman
Merck Posts Lower Revenue and Profit -- 2nd Update
Charter Communications Loss Widens on Merger Costs
Star Wars' Is the Force Behind Strong Hasbro Sales -- Update
Wells To Pay $1.2 Billion In Mortgage Accord
Pfizer Files 8K - Changes Executive Management
Redbox Movie Rentals Plunge 24%
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 199601 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist